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Background: Human papillomavirus (HPV) has long been proposed as a cofactor in
the pathogenesis of cutaneous squamous cell carcinoma (cSCC). More recently, the
striking clinico-pathological features of cSCCs that complicate treatment of metastatic
melanoma with inhibitors targeting BRAF mutations (BRAFi) has prompted speculation
concerning a pathogenic role for oncogenic viruses. Here, we investigate HPV and
human polyomaviruses (HPyV) and correlate with clinical, histologic, and genetic
features in BRAFi-associated cSCC.
Materials and Methods: Patients receiving BRAFi treatment were recruited at
Barts Health NHS Trust. HPV DNA was detected in microdissected frozen samples
using reverse line probe technology and degenerate and nested PCR. HPV
immunohistochemistry was performed in a subset of samples. Quantitative PCR was
performed to determine the presence and viral load of HPyVs with affinity for the skin
(HPyV6, HPyV7, HPyV9, MCPyV, and TSPyV). These data were correlated with previous
genetic mutational analysis of H, K and NRAS, NOTCH1/2, TP53, CDKN2A, CARD11,
CREBBP, TGFBR1/2. Chromosomal aberrations were profiled using single nucleotide
polymorphism (SNP) arrays.
Results: Forty-five skin lesions from seven patients treated with single agent
vemurafenib in 2012–2013 were analyzed: 12 cSCC, 19 viral warts (VW), 2 actinic
keratosis (AK), 5 verrucous keratosis/other squamoproliferative (VK/SP) lesions, one
melanocytic lesion and 6 normal skin samples. Significant histologic features of viral
infection were seen in 10/12 (83%) cSCC. HPV DNA was detected in 18/19 (95%)
VW/SP, 9/12 (75%) cSCC, 4/5 (80%) SP, and 3/6 (50%) normal skin samples and in
1/12 cases assessed by immunohistochemistry. HPyV was co-detected in 22/30 (73%)
of samples, usually at low viral load, with MCPyV and HPyV7 the most common. SNP
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arrays confirmed low levels of chromosomal abnormality and there was no significant
correlation between HPV or HPyV detection and individual gene mutations or overall
mutational burden.
Conclusion: Despite supportive clinicopathologic evidence, the role for HPV and HPyV
infection in the pathogenesis of BRAFi-induced squamoproliferative lesions remains
uncertain. Synergistic oncogenic mechanisms are plausible although speculative.
Nonetheless, with the prospect of a significant increase in the adjuvant use of these
drugs, further research is justified and may provide insight into the pathogenesis of
other BRAFi-associated malignancies.
Keywords: human polyomaviruses, human papillomaviruses, cutaneous squamous cell carcinomas, BRAF
inhibitors, melanoma
INTRODUCTION
Human papillomaviruses (HPV), particularly those of the beta
genus (beta-PV), have long been proposed as cofactors with
ultraviolet radiation in the pathogenesis of cutaneous squamous
cell carcinoma (cSCC), especially those associated with the
rare genodermatosis, epidermodysplasia verruciformis and with
immune suppression (Wang et al., 2014; Howley and Pfister,
2015; Quint et al., 2015; Harwood et al., 2017). Over the
past decade, 13 human polyomaviruses (HPyV) have been
identified and classified (Calvignac-Spencer et al., 2016) and
those with affinity for the skin include HPyV6, HPyV7, HPyV9,
the trichodysplasia spinulosa-associated polyomavirus (TSPyV),
the Merkel cell polyomavirus (MCPyV) (DeCaprio and Garcea,
2013; Feltkamp et al., 2013; van der Meijden et al., 2010, 2013;
Nguyen et al., 2017) and the Lyon IARC polyomavirus (LIPyV)
(Gheit et al., 2017). MCPyV was the first to be associated with
malignancy – the aggressive cutaneous neuroendocrine cancer
Merkel cell carcinoma (Feng et al., 2008; Shuda et al., 2008) – and
has also been investigated in the context of cSCC (Dworkin et al.,
2009; Scola et al., 2012). More recently, the clinical and histologic
features of cSCCs and other squamoproliferative lesions that
complicate treatment for metastatic melanoma with oral small
molecule BRAF inhibitors (BRAFi) have raised the possibility of
significant viral involvement in their pathogenesis (Boussemart
et al., 2013). Both HPV and HPyV have been investigated, but
studies have to date provided conflicting evidence for their role.
With the prospect of future widespread adjuvant use of these
drugs (Long et al., 2017; Maio et al., 2018), a more detailed
understanding of the pathogenesis of BRAFi-induced cSCC
(BRAFi-SCC) remains important.
Oncogenic mutations in the oncoprotein BRAF, which
encodes the growth signal transduction serine/threonine protein
kinase B-Raf, are found in approximately 50% of melanomas
and result in constitutive activation of the RAS/mitogen-activated
protein kinase (MAPK) pathway. The most common BRAF
mutation results in a substitution of a valine (V) residue to
glutamic acid (E) at amino acid position 600 (V600E) (Long
et al., 2011). This locks the kinase into the active conformation
and results in melanocyte hyperproliferation. BRAF inhibitors
have been developed that exploit this mutation and competitively
bind to the active conformation of the kinase (Zhang et al., 2009;
Ribas and Flaherty, 2011) Vemurafenib and dabrafenib are two
such selective small molecule inhibitors of oncogenic BRAF
and are associated with high response rates and improved
progression-free survival and overall survival compared with
chemotherapy in patients with BRAFV600 mutated melanoma
(Chapman et al., 2017). However, responses are generally
temporary, with a median time to relapse of approximately
6 months. Vemurafenib entered routine clinical use in 2011/2012
and has been associated with various cutaneous adverse
effects. These include rashes, photosensitivity, hyperkeratosis
and development of de novo squamoproliferative lesions in
16–26.7% of patients, ranging from benign VW and squamous
papillomas/verrucous keratoses (VK) to keratoacanthomas (KA)
and cSCC (Flaherty et al., 2010; Sosman et al., 2012; Anforth et al.,
2013; Blank et al., 2017; Chapman et al., 2017). The median time
to presentation for BRAFi-SCC is 8–12 weeks and it is argued
that this rapid timeframe points to pre-existing mutations being
given a selective advantage due to BRAFi treatment, rather than
mutations arising de novo due to therapy. Consistent with this
mechanism, there is evidence for paradoxical hyperactivation of
the MAPK pathway in cells with wild-type BRAF but mutated
RAS through allosteric and catalytic mechanisms that relieve the
auto-inhibition of wild-type RAF kinase (Hatzivassiliou et al.,
2010; Heidorn et al., 2010; Poulikakos et al., 2010). Indeed,
many of these BRAFi features overlap with the cutaneous
manifestations of RASopathies – genetic diseases such as
cardiofaciocutaneous and Costello syndromes characterized by
activating germ line mutations in RAS (Rinderknecht et al.,
2013; Sfecci et al., 2017). Also consistent with this, 18–60% of
BRAFi-cSCC have somatic mutations in HRAS or KRAS, which
is significantly higher than in sporadic cSCC (Oberholzer et al.,
2012; Su et al., 2012; South et al., 2014). Nevertheless, many
BRAFi-cSCC are RAS wild type, and RAS mutations have been
also been detected in benign epithelial skin lesions (South et al.,
2014; Hassel et al., 2015), suggesting that accelerated oncogenesis
of RAS-mutated cells is not the only aetiologic mechanism and
that additional cofactors may be involved. Attention has focused
on infectious agents, particularly oncogenic viruses. HPV has
been the main candidate given its previous proposed role in
EV and immune suppression-associated cSCCs, coupled with
evidence in BRAFi-cSCC of clinical and histological patterns of
viral wart-like features and overexpression of p16 (Boussemart
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et al., 2013). Human polyomaviruses, particularly MCPyV, have
also been investigated but, to date, the available evidence for both
HPV and HPyV remains inconclusive (Anforth et al., 2012; Chu
et al., 2012; Boussemart et al., 2013; Ganzenmueller et al., 2013;
Falchook et al., 2013, 2016; Ko et al., 2013; Frouin et al., 2014;
Holderfield et al., 2014; Schrama et al., 2014; Cohen et al., 2015;
Dika et al., 2015; Viarisio et al., 2017a,b).
Single agent BRAFi therapy has generally been replaced
by combination BRAFi and MEK inhibition (MEKi): phase
III studies demonstrated improved clinical outcomes and
significantly delayed resistance compared with BRAFi alone and
BRAFi-MEKi combination therapy (vemurafenib/cobimetanib
and dabrafenib/trametinib) is now the standard of care for
BRAF mutated metastatic melanoma (Flaherty et al., 2012; Larkin
et al., 2014). Combination therapy also results in decreased
incidence of BRAFi-SCC to around 4%, which may be due
to the fact that MEKi bypasses the point of paradoxical RAF
activation (Dummer et al., 2012). Although rates of BRAFi-
SCC are consequently reduced with combination therapy, these
drugs are now being introduced as adjuvant treatment in high-
risk, non-metastatic primary melanoma (stages IIC–IIIA–IIIB–
IIIC). In the recent BRIM-8 study of adjuvant vemurafenib in
BRAF-mutated melanoma, 16% of patients treated with adjuvant
vemurafenib had BRAFi-cSCC or KA (Maio et al., 2018). This
incidence is considerably lower with BRAFi-MEKi combination
adjuvant therapy (Long et al., 2017), but with approval for
adjuvant treatment comes the prospect of a huge increase in the
numbers of patients receiving these agents in the near future. The
need to better understand the pathogenesis of their associated
cSCC therefore remains important.
In this study we have examined HPV and HPyV status in
a series of benign and malignant BRAFi-associated skin lesions
and correlated these data with key clinical, histologic and genetic
parameters in order to further investigate the contribution of
these viruses to the pathogenesis of BRAFi-induced skin tumors.
MATERIALS AND METHODS
Patients and Samples
Patients were recruited from the melanoma clinic at Barts
Health NHS Trust. Punch biopsies were taken after surgical
excision of lesions or from bisected shave biopsies. They
were immediately snap-frozen in liquid nitrogen and stored
at −80◦C. The remainder of the tissue was sent for formalin
fixation and histologic diagnosis. In order to enrich for
tumor cell populations, fresh-frozen samples were laser-capture
microdissected using the Zeiss Palm Microbeam microscope
(Zeiss, Cambridge, United Kingdom). Depending on sample
size and purity, as estimated from a reference hematoxylin and
eosin slide, between 30 and 60 sections of 8 mm thickness
were cut onto 1.0 mm PEN membrane slides (Zeiss), stained
in 0.05% acid fuchsin (Acros Organics, Morris Plains, NJ,
United States) in distilled water and 0.05% toluidine blue
O (Acros Organics, Morris Plains, NJ, United States) in
70% ethanol, and microdissected, with tumor cells collected
into 180 µl ATL buffer (Qiagen, Crawley, United Kingdom).
All sections were cut using a fresh microtome to prevent
cross-contamination. DNA extraction was performed using the
QIAamp DNA micro kit (Qiagen, Crawley, United Kingdom)
according to the manufacturer’s instructions. To provide a source
of germline DNA, paired venous blood samples were obtained
concomitantly with lesional tissue and stored at −80◦C before
DNA extraction using the QIAamp DNA blood mini kit (Qiagen,
Crawley, United Kingdom). The quality of the extracted DNA
was assessed by β-globin reference gene PCR.
Histopathology
Histology sections were prepared from formalin-fixed paraffin-
embedded tissue and stained with hematoxylin and eosin
under standard conditions. All diagnoses were confirmed after
review by an experienced dermatopathologist (HR). Samples
were scored as having features consistent with viral infection
if koilocytosis was observed in conjunction with at least three
of the following five features: acanthosis, hypergranulosis,
parakeratosis, hyperkeratosis, and typical papillomatous
architecture. Consensus scoring of viral features was reached
with two additional observers (KP, CH).
HPV Detection and Genotyping
Beta, gamma, alpha, mu, nu, and novel HPV types were detected
using a comprehensive panel of HPV detection and typing
methodologies. The presence of beta-HPV was investigated using
RHA kit skin (beta) HPV detection system (de Koning et al.,
2006) according to the manufacturer’s instructions (Diassay,
Rijswijk, The Netherlands). In addition, the RHA kit HPV
SPF10-LiPA25 (Labo Bio-medical products BV, Rijswijk, The
Netherlands) was used to detect the presence of 25 high- and low-
risk mucosotropic alpha-HPVs, according to the manufacturer’s
instructions. Degenerate nested PCR protocols were used to
investigate the presence of cutaneous alpha-HPV and mu and nu
genera (Harwood et al., 1999) and the gamma genus (Forslund
et al., 1999; Antonsson et al., 2000).
Polyomavirus Detection and Genotyping
In lesional samples for which sufficient DNA was available,
quantitative PCR was performed as previously described (van
der Meijden et al., 2014, 2017), to determine the presence
and load of HPyV9, MCPyV, and TSPyV. For HPyV6 and
HPyV7 quantitative PCR the following primers and probes
located in VP1 were used: 5′-GTAGGGTATGCTGGTAAC-3′
(HPyV6 sense), 5′-CAGGAATTGTCTAAACATCATATC-3′
(HPyV6 antisense), 5′-CTCTCCTCTGTCTGAAGTGAACTC-
TAA-3′ (HPyV6 probe), 5′-GTGCTGATATGGTTGGAA-3′
(HPyV7 sense), 5′-TCTGCAGTGGACTCTAAA-3′ (HPyV7
antisense), 5′-AGCCTGTACTGTTCTCTGGTTACT-3′ (HPyV7
probe). Input cell equivalents were determined by normalization
to beta-globin.
All DNA extractions and PCRs for both HPV and HPyV
were performed using standard operating procedures designed to
reduce the possibility of contamination (Harwood et al., 1999).
DNA extraction, water and buffer PCR controls were used to
exclude contamination and these were consistently negative.
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Immunohistochemistry
Immunofluorescence analysis was carried out using polyclonal
antibodies raised against the E4 proteins of HPV 5, 8, and 23
(beta-PV types), or the E4 protein of HPV2 and 57 (alpha-
PV types) using the protocols previously described (Griffin
and Doorbar, 2016). In the double staining experiments, a
monoclonal antibody (8H3) prepared against the HPV 8 E4
protein was used in place of the beta-PV E4 polyclonal antibodies.
Polyclonal and monoclonal antibodies were prepared against
GST-E4 fusion proteins (Doorbar et al., 1997; Borgogna et al.,
2012). Techniques for the overlay of fluorescence staining
patterns onto the hematoxylin and eosin sections have been
described previously (Griffin et al., 2015). All tissue sections were
formalin fixed prior to staining. Sections were counterstained
with DAPI to visualize cell nuclei.
SNP Array Analysis of Gross
Chromosomal Aberrations
Cutaneous squamous cell carcinoma and paired venous blood
DNA samples were subjected to the GeneChip Genome-
Wide Human SNP Array 6.0 assay (Affymetrix Inc., Santa
Clara, CA, United States) according to the manufacturer’s
protocol. Processing was performed as previously described
(Teh et al., 2005) using the Genome Oriented Laboratory
File (GOLF) system for the analysis and display of single
nucleotide polymorphism (SNP) signal data. Copy number
profiles of vemurafenib-associated cSCC were compared with
those observed in a previous study of sporadic cSCC (Purdie et al.,
2009).
Genetic Mutational Analysis
Targeted genetic analysis of all samples was undertaken
using 454 pyrosequencing performed using the GS Junior
system (Roche/454 Life Sciences, Branford, CT, United States)
and Fluidigm (Fluidigm Corporation, San Francisco, CA,
United States) PCR amplicon libraries as template. In addition to
H, K, and NRAS, we also analyzed the genes NOTCH1, NOTCH2,
TP53, CDKN2A, CARD11, CREBBP, TGFBR1, and 2, all of
which our previous research has implicated in the pathogenesis
of cSCC (Brown et al., 2004; South et al., 2014; Cammareri
et al., 2016; Watt et al., 2015, 2016). Primers were designed and
validated by Fluidigm (Fluidigm Corporation, San Francisco,
CA, United States) as per recommended guidelines for Roche
Titanium sequencing (Roche, Mannheim, Germany). Variant
detection required a minimum of four supporting reads and
a minimum variant allele frequency threshold of 0.1. Detailed
genetic analysis of these samples has previously been reported
(South et al., 2014; Cammareri et al., 2016).
Ethical Approval
This study was carried out in accordance with the
recommendations of East London and City Health Authority
local ethics committee. The protocol was approved by the East
London and City Health Authority local ethics committee. All
subjects gave written informed consent in accordance with the
Declaration of Helsinki.
RESULTS
Patients
A total of seven patients with 45 skin lesions were recruited
(Figures 1, 2 and Table 1). They included 4 men (mean
age 61.25 years, range 35–87 years) and 3 women (mean age
56.3 years, range 33–82 years). All patients had metastatic
melanoma with V600E BRAF mutations. All were treated in
2012–2013 with single agent vemurafenib. For all patients,
samples were collected at first presentation with skin lesions
after starting vemurafenib. The mean time to either disease
progression (n = 3 patients) or death from melanoma whilst
receiving vemurafenib (n = 4 patients) was 7.7 months (range
3–17 months).
Samples (Table 1)
Samples consisted of 12 SCC, 19 VW, 2 actinic keratoses (AK),
one melanocytic lesion and 6 non-lesional skin samples (3 normal
skin and 3 normal skin perilesional to cSCC), 4 verrucous
keratoses (VK – squamous papillomas, some with viral features
but without evidence of dysplasia) and one squamoproliferative
(SP) lesion with viral features and dysplasia but no clear invasion
(SP). Lesions were from both chronically sun-exposed (SE) and
non-chronically sun-exposed (NSE) sites. SE sites included head
and neck, arms, and lower legs in females. NSE included all other
sun-protected sites. Lesions from SE sites included 6/12 (50%)
cSCCs, 5/5 VKs, 9/19 (47%) VWs, and 1/2 AKs. The normal skin
samples comprised 2 SE, one NSE and 3 perilesional to SCCs on
SE sites.
The mean time to development of biopsy-proven lesions after
initiation of vemurafenib was 8.75 weeks for AK (range 6–11.25),
9.7 weeks for VK/SP (range 8–12), 9.9 weeks for VW (range 6–
13), and 11.25 weeks for cSCC (range 8–16 weeks). For 2 patients,
additional samples were collected at more than one further time
point: for patient 1, samples were collected at 9, 13, 14, 18, and
34 weeks; for patient 2, at 9 and 28 weeks.
Histopathology
Significant histological features of viral infection (i.e., koilocytosis
and at least three of acanthosis, hypergranulosis, parakeratosis,
hyperkeratosis or typical papillomatous architecture) were seen
in all VW and AKs, 10/12 (83%) SCC, but no normal skin or VK
samples (Figure 3 and Table 1).
Detection of Human Papillomavirus and
Human Polyomaviruses
Human Papillomavirus Detection
Human papillomavirus DNA was detected in 18/19 (95%) VW,
9/12 (75%) SCC, 2/2 AK, 4/5 (80%) VK/SPs, and 3/6 (50%)
normal skin samples (Table 1). HPV positivity was significantly
higher in VW compared to normal skin (Fisher’s exact test:
p = 0.0312,) but not in cSCC (Fisher’s exact test: p = 0.344).
Multiple HPV types were detected in 28/37 (76%) of HPV
positive samples, with a median number of 4 in VW and 3 in SCC
compared with 0.5 in normal skin (two-sided Mann–Whitney
U-test: p = 0.007 for VW and 0.13 for SCC).
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FIGURE 1 | Viral-wart like lesions developing after BRAFi exposure. (A) Lesion V10, viral wart on chin of patient 2; (B) Viral warts on the neck and chin of patient 1;
(C) Viral wart on the eyelid of patient 5; (D) Lesion V22, post-auricular viral wart in patient 3.
FIGURE 2 | Cutaneous squamous cell carcinomas developing after BRAFi
exposure. (A) Well-differentiated SCC on the ear of patient 1; (B) Lesion V4,
well-differentiated SCC on the arm of patient 1.
Cutaneous beta-PV were detected in all HPV positive lesions,
with HPV-8, 12, 24, 36, and 92 the most frequent types. Alpha
genus HPV types (alpha-PV) were found VW only (4/19, 21%)
and were mucocutaneous alpha-PVs (HPV28 and HPV57), but
not low or high-risk mucosal alpha-PVs. One cSCC contained
a gamma HPV type. Although the RHA detection methodology
used for beta and alpha-PV detection is not strictly quantitative,
band intensity provides a surrogate read-out for predicted viral
load. Analysis of these data suggested that the majority of HPV
positive samples were likely to be associated with low viral load:
the bands identified were faint or very faint in all cases, with the
exception of samples V10, V18, V20, V29, V44 in which strongly
positive bands were obtained for HPV types 57, 12, and 80. Four
of these five lesions were VWs.
In all patients except one, multiple lesions were analyzed.
Clear patterns of HPV carriage for each individual emerged.
For example, beta-PVs 8, 12, 24, 36, 92, 93, and 111 were
detected in patient 1 across both benign and malignant lesions
at different body sites; this patient’s normal, non-sun exposed
skin sample also harbored HPV92 in addition to HPV5. Patient
2 had a spectrum of HPV types (HPV8, 12, 76, 80, and 57) that
were concordant in VW at two separate body sites. Three other
patients with more than one HPV positive lesion also had similar
individual repertoires of HPV types across at least 2 lesions
(patient 3, HPVs 22, 107; patient 4, HPV9; patient 7, HPV80).
In the case of patient 6, all samples were negative, including two
normal skin samples.
Only a minority of the 36 lesions with significant viral
features on histological assessment had high levels of HPV DNA
indicative of active infection. However, the 9 samples with no
histological evidence of viral change (one cSCC, 2 VKs and 6
normal/perilesional skin samples) had significantly fewer HPV
types detected compared to lesions with histological evidence of
viral change (2-tailed Mann–Whitney U-test: p = 0.0114).
Immunohistochemistry was used to further investigate HPV
DNA detection in a subset of 12 lesions. Although all had
been HPV positive with multiple types detected, HPV protein
expression was detected in only a single sample, a viral wart
that had been strongly positive for both HPV57 and HPV80:
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FIGURE 3 | Histology of lesion V4: Micro invasion in an SCC from patient 1
with features of viral infection in overlying and adjacent epidermis.
both HPV57 and beta-PV were detected, but were expressed in
spatially distinct cells within the lesion (Figure 4).
Human Polyomavirus Detection
Thirty lesional samples from 5 individuals were tested for the
presence of HPyV (VW, n = 12; SCC, n = 11; VK/SP, n = 4;
AK, n = 2; melanocytic, n = 1). Normal skin was not examined.
The majority of samples were positive for at least one HPyV,
albeit at low levels and independent of the presence or absence of
significant histological viral features (Table 1). Individual HPyV
positivity ranged from 0% positivity for TSPyV; 3.3% for HPyV9
(SCC, n = 1); 33% for HPyV6 (VW, n = 3, 25%; SCC, n = 4,
36%; VK, n = 3, 36%); 60% for HPyV7 (VW, n = 8, 67%; SCC,
n = 6, 54%; VK, n = 3, 25%; AK, n = 1, 50%) to 73% positivity
for MCPyV (VW, n = 9, 75%; SCC, n = 8, 73%; VK, n = 3, 75%;
AK, n = 1, 50%; melanocytic, n = 1, 100%). For all viruses, the
difference in positivity between BRAFi-cSCC and VW was not
significant (Fisher’s exact test: p = 1 for HPyV9, HPyV6, MCPyV;
p = 0.68 for HPyV7). Viral loads were generally less than one copy
per thousand cells. The exceptions were four HPyV7-positive
benign samples with viral loads ranging from 1 copy per 100 cells
to one copy per seven cells and eight MCPyV-positive samples
(two cSCC with viral loads of 2–5 copies per 100 cells and six
benign lesions with viral loads from 1 copy per 100 cells to 1 copy
per 4 cells).
Co-detection of HPV and HPyV
At least one HPV type and one HPyV type were co-detected
in 22/30 (73%) of lesions. There was no significant correlation
between specific HPV and HPyV types. However, it was
noteworthy that lesions from patient 6, which were all negative
for HPV, were also largely negative for HPyV, despite having
significant histological features of viral infection. Similarly, the
cSCC for patient 4 was negative for all beta-PV and HPyV types
tested.
Virus Status and Chromosomal Changes
In order to examine gross chromosomal aberrations in
vemurafenib-associated sSCC, we analyzed six well-differentiated
cSCC from patient 1 using SNP array analysis to determine
the signal values in tumor and paired non-tumor DNA at
250,000 SNPs throughout the genome. A comparison of tumor:
non-tumor signal value ratios from vemurafenib-associated
cSCC plotted according to chromosomal position with those
from sporadic well-differentiated SCC analyzed in a previous
study (Purdie et al., 2009) revealed that the patterns of gross
chromosomal aberrations were significantly different: none of
these 6 cSCC had gross chromosomal aberrations and there
were significantly fewer chromosomal changes compared with
sporadic well differentiated SCC (Figure 5). There were no clear
correlations with virus status identified.
Virus Status and Association With
Specific Genetic Mutations
We have reported gene mutations identified by targeted
sequencing in these 45 samples for H, K and NRAS, NOTCH1 and
2, TP53, CDKN2A, CARD11, CREBBP, TGFBR1/2 and this has
previously been presented in detail (South et al., 2014; Cammareri
et al., 2016). In the current study we analyzed the association
between these mutations and the presence of HPV and HPyV.
HRAS mutations were identified in 5/12 (42%) SCC and 5/19
(31%) VW. Mutation did not correlate with sun-exposed sites
or lesion type and no mutations were detected in normal skin
samples (Table 1). There was no significant difference between
HRAS mutated vs. HRAS wild type lesions and HPV or HPyV
status. The same was true for virus status and mutations in each
of the other genes examined. Although it was noteworthy that
v35 – the most highly mutated SCC – was negative for all viruses
tested, there was no evidence of a significant correlation between
overall mutational burden and virus status.
Virus Status and Clinical Response to
Vemurafenib
There was no clear evidence of a significant association between
virus status of lesions tested and prognosis in terms of disease
progression and death from melanoma (data not shown).
DISCUSSION
We report HPV and HPyV analysis of 45 benign and malignant
BRAFi-induced skin lesions from 7 individuals, including
BRAFi-SCC and correlate this with clinical, histologic and genetic
features. A high proportion of BRAFi-cSCCs had histologic
viral wart-like features on histology, consistent with virus-driven
processes, and the majority were positive for beta-PV, HPyV7 and
MCPyV, which were co-detected in 73% of lesions tested. HPyV6
was found in one third of cases, but HPyV9 and TSPyV were
rarely detected. As expected from previous studies of normal skin
and hair follicles (Harwood et al., 2004; Bouwes Bavinck et al.,
2010, 2017; Proby et al., 2011), normal skin samples also harbored
beta-PV, but the HPV burden of individual types detected was
significantly fewer than in lesional skin. Histologic evidence of
virus infection appeared to correlate with HPV burden. However,
viral loads were low in the majority of lesions and validation
by immunohistochemistry for HPV was negative in all but
one of 12 cases. Gross chromosomal changes characterized by
SNP arrays in BRAFi-cSCC indicated that these tumors have
Frontiers in Microbiology | www.frontiersin.org 9 August 2018 | Volume 9 | Article 1806
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FIGURE 4 | Human papillomavirus immunohistochemistry. (A,D) Hematoxylin and eosin stained sections of 2 different areas of lesion V10 (strongly PCR positive for
beta-PV types 8, 12, 76, 80, and alpha-PV 57); (B,E) double staining immunofluorescence with antibodies to the E4 protein of HPV8 (green) and HPV2/57 (red);
(C,F) H&E stained sections overlaid with the images from immunofluorescence microscopy to identify cells with productive HPV infection.
significantly fewer chromosomal aberrations than non-BRAFi-
cSCC, providing a further indication that additional cofactors
may be involved. However, we were unable to establish clear
correlations between the presence of either HPV or HPyV and
specific genetic mutations or total mutational burden.
Human Papillomaviruses and
BRAFi-cSCC
Human papillomaviruses has been investigated as a potential
viral carcinogen in BRAFi-cSCC since these drugs were first
approved in 2011/2012: the rapid onset of skin lesions, their
clinical morphology and viral wart-like histology all point to a
possible role for HPV (Boussemart et al., 2013). Initial studies
designed to detect alpha-PV infection by immunohistochemistry
reported negative results (Anforth et al., 2012; Chu et al., 2012;
Ko et al., 2013). A surrogate for alpha-PV infection in mucosal
sites is p16 immunoreactivity and in two studies the majority
of BRAFi-cSCC were found to strongly express p16 (Anforth
et al., 2012; Boussemart et al., 2013), but this is not a consistent
finding (Frouin et al., 2014). Both approaches are less sensitive
than PCR-based detection methodologies that have been used
in other studies, although the latter are often limited by the use
of formalin-fixed paraffin-embedded tissue (FFPE) and/or PCR
primers detecting a limited range of HPV types. Using an alpha-
PV specific PCR/line probe assay method, Dika et al failed to
detect alpha-PV in 9 FFPE VK samples (Dika et al., 2015). Using
the same assay together with a degenerate PCR methodology
(FAP59/64) capable of detecting cutaneous HPV types, HPV
was not detected in 8 BRAFi-cSCC/KA FFPE samples (Frouin
et al., 2014). Holderfield et al used the FPA 59/64 primers and
additional degenerate primers (CP65/CP70 and CP66/CP69) and
found 2/13 (15%) FFPE BRAFi-cSCC (Holderfield et al., 2014).
Schrama et al. (2014) used E1 primers originally tested for alpha-
PV types but theoretically capable of detecting any HPV type;
in FFPE samples from 14 cSCC, 3 KA and one acanthoma,
all were HPV positive, although the specific types detected
were not reported. Subsequently, Cohen et al. (2015) used the
most comprehensive degenerate PCR-based methodology in 69
FFPE BRAFi-cSCC and found all samples to be positive with
predominantly beta-PV types of which HPV-17, HPV-38 and
HPV-111 were the most common. Falchook et al. (2016) found
6/12 (50%) FFPE BRAFi-cSCCs to be positive, almost exclusively
with beta-PV types including 12, 17, 24, 47, 124 and novel types
but, as in our study, HPV positivity was not significantly different
when compared to normal skin. However, we found a significant
difference in HPV burden between lesional and normal skin in
terms of the numbers of HPV types detected and it is possible
that the total burden of HPV types as well as the specific types
detected is relevant to potential pathogenic processes.
Against the background of these previous studies, our HPV
detection methodology has notable strengths, although the data
are still limited by small sample size. We have used a more
comprehensive and sensitive approach to detecting HPV from
alpha, beta, mu, nu, gamma genera with RHA and degenerate
PCR/sequencing. We have also used fresh frozen tissue samples
in order to reduce the likelihood of false negative results, which
may occur with use of FFPE-derived DNA. Laser capture micro
dissection allowed enrichment for lesional tissue and reduces the
possibility of contamination by virus carriage in non-lesional
tissue. Neither strategy for optimizing viral detection has
been used in these previous studies. In addition, we used
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FIGURE 5 | SNP microarray analysis of vemurafenib-associated cSCC. BRAFi-SCC did not display the gross chromosomal aberrations typically observed in
sporadic cSCC (Purdie et al., 2009). A running average of 2 consecutive tumor: non-tumor signal value ratios is plotted on a log2 scale according to chromosomal
position. Upper line represents log2(2) and lower represents log2(0.5). (A) Copy number profiles of 5 vemurafenib-associated cSCC (B) Comparison with copy
number profile from a sporadic cSCC showing 3p and 9p loss: these changes were characteristic of well-differentiated cSCC (Purdie et al., 2009). Although
chromosome 18 loss is also seen in this particular tumor, chromosome 18 aberrations were not as common as 3p and 9p changes in other sporadic
well-differentiated cSCC (Purdie et al., 2009). (C) More extensive allelic imbalance in a sporadic moderately-differentiated cSCC (Purdie et al., 2009).
immunohistochemistry to try and understand the nature and
significance of multiple HPV detection using a double staining
technique not used in previous studies of BRAFi lesions.
Our study was not designed to address the functional
significance of HPV detection in BRAFi-associated
squamoproliferative skin lesions. To date, this has been
attempted in only a few other studies. Ganzenmueller et al.
(2013) used next-generation sequencing to look for viral
transcripts indicative of active HPV infection: none were
identified in 4 BRAFi-associated VK. Although this small study
arguably calls into question a role for HPV, it is important to
note that BRAFi-cSCC were not examined and the presence of
very low abundance transcripts cannot be entirely excluded. In
a compelling experimental approach, exposure to vemurafenib
in a transgenic murine model (K14-HPV16 mice) of alpha-
PV-driven cSCC was associated with an upregulation of the
MAPK pathway and an increase in cSCC incidence from 22
to 70%. More than half of these tumors were RAS wild type,
suggesting that vemurafenib and HPV may be cooperating to
promote tumorigenesis in both the presence and absence of
RAS mutations (Holderfield et al., 2014). Data from a more
recent beta-PV transgenic mouse model provides evidence of
significant synergism between beta-PV, UV, and BRAFi (Viarisio
et al., 2017a). The K14-HPV38 E6/E7 transgenic mouse expresses
the beta-PV HPV38 E6 andE7 oncogenes in the basal layer of the
epidermis under the control of the cytokeratin K14 promoter and
requires UV exposure for AK and cSCC development (Viarisio
et al., 2011). Vemurafenib increased the number and size of
UV-induced cSCC. All BRAFi-treated transgenic mice developed
cSCC by 34 weeks in contrast to none of the wild-type mice and
only one-third of untreated transgenic mice. Ras mutations were
not detected, but MAPK upregulation was evident in HPV38
E6/E7 over-expressing keratinocytes (Viarisio et al., 2017a).
The mechanisms responsible for the synergism between
HPV and BRAFi are speculative. However, experimental data
indicate that upregulation of the MAPK pathway enhances
alpha-PV replication, stability, and infectivity (Wang et al.,
2009; Bowser et al., 2011). If this is also the case for other
HPV types, then it is possible that BRAFi-induced paradoxical
upregulation of MAPK in the keratinocytes of normal skin –
which is likely to harbor beta-PV HPV (Harwood et al., 2004;
Bouwes Bavinck et al., 2010, 2017; Proby et al., 2011) – also leads
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to enhanced replication and stability of these beta-PV. The
resulting increased beta-PV viral load in normal keratinocytes
may drive not only benign squamoproliferative lesions associated
with BRAFi, but may also enhance synergism between the
oncogenic effects of beta-PV and UV, independent of RAS status,
which ultimately leads to increased carcinogenesis in the K14-
HPV38-E6/7 transgenic murine model (Viarisio et al., 2017a).
Consistent with this, experimental evidence increasingly points
to a “hit and run” role for beta-PV in skin (Tommasino, 2017).
In contrast to high-risk alpha-PV which are required for both
initiation and maintenance of a malignant phenotype in mucosal
carcinogenesis, the hit-and-run hypothesis proposes that beta-
PVs are required only at an early stage of carcinogenesis, with
beta-PV E6 and E7 oncogenes facilitating accumulation of UV-
induced DNA mutations in the host genome by means of
multiple mechanisms that, for example, target DNA repair and
apoptosis leading to inactivation of cellular tumor suppressor
proteins or activation of oncoproteins (Connolly et al., 2014;
Howley and Pfister, 2015; Quint et al., 2015; Tommasino, 2017;
Viarisio et al., 2017b). This is the “hit,” which ultimately leads
to cellular transformation (Viarisio et al., 2017b). Viral oncogene
expression is subsequently not required for maintenance of a
malignant phenotype, rendering the viral genome dispensible
and without consequence if lost from an established cancer –
the “run.” This would explain the observations that beta-PV
DNA loads are always significantly less than one viral genome
copy per cell in cSCC and are generally higher in precancerous
AK (Weissenborn et al., 2005), that viral transciptomes are
absent from BRAFi and non-BRAFi-cSCC (Arron et al., 2011;
Ganzenmueller et al., 2013), and are supported by together with
findings in the recent murine K14-HPV38E6/7 transgenic models
(Viarisio et al., 2018). However, although biologically plausible,
this hypothesis remains to be definitively confirmed in human
studies.
Such a hit-and-run role for beta-PV may also potentiate the
deleterious effects of cSCC cofactors such as immune suppression
and contribute to the higher susceptibility to cSCC of immune
suppressed individuals such as solid organ transplant recipients
(Harwood et al., 2017). We and others have previously shown
that beta-PV carriage is significantly more common in the
normal skin and hair follicles of immune suppressed individuals
(Weissenborn et al., 2012) and, particularly in the presence of
concordant beta-PV seropositivity, is associated with cSCC risk
in both OTR (Proby et al., 2011; Bouwes Bavinck et al., 2017)
and immunocompetent individuals (Bouwes Bavinck et al., 2010;
Chahoud et al., 2016). Although detailed comparison of virus
status in BRAFi- and non-BRAFi-associated cSCC might provide
insight into the effects of BRAFi on the biological activity of
beta-PV in skin, the small numbers of published studies in
BRAFi-cSCC and the wide variations in HPV analyses used in
these studies limit the power of such an analysis.
Human Polyomaviruses and
BRAFi-cSCC
We detected HPyV6 in one third of all 30 lesions tested, HPyV7
in 60% and MCPyV in 73%, with no significant differences seen
between benign and malignant lesions. In most cases the loads
for all viruses were low. In our series HPyV9 was negative in all
cases and TSPyV positive in just one cSCC. Our data for MCPyV
are very similar to the 72% positivity reported in a series of 18
FFPE BRAFi-cSCCs (Schrama et al., 2014) and 75% of 12 BRAFi-
cSCC (Falchook et al., 2016). In contrast, Cohen et al detected
MCPyV in only 22% of 58 FFPE benign and malignant FFPE
lesions (Cohen et al., 2015) and a fourth study found MCPyV in
only two of 19 VKs and none of 7 cSCCs (Frouin et al., 2014). Of
the few studies to examine other HPyVs, Schrama et al. (2014)
found HPyV6 and 7 in all FFPE samples (14 cSCC, 3 KA, and one
acanthoma), generally at low levels, although HPyV6 was present
at high level and detectable by IHC in one cSCC. In contrast, in
FFPE samples of 19 VKs, 1KA and 7 cSCC, Frouin et al. (2014)
found no HPyV6 positivity and HPyV7 in one VK only. Once
again, in all previous studies samples were FFPE rather than
frozen samples and this, together with the tumor enrichment and
PCR approaches used in our study, may account for some of these
differences in HPyV detection.
We did not test normal skin samples, but MCPyV, HPyV6 and
7 are well-established members of the normal skin virome, with
HPyV9 and TSPyV significantly less common (Schowalter et al.,
2010; Foulongne et al., 2012; Kazem et al., 2012; Wieland et al.,
2014). MCPyV has previously been detected in 40–62% of skin
swabs from normal individuals (Wieland et al., 2009; Schowalter
et al., 2010) and HPyV6 and 7 have been detected in 14 and 11%,
respectively (Schowalter et al., 2010). In comparison, HPyV9
and TSPyV were found in skin swabs from only 1/111 (0.9%)
and 6/249 (2%) healthy individuals, respectively (Sauvage et al.,
2011; Kazem et al., 2012). A previous study analyzed MCPyV
in 9 FFPE normal skin biopsies from patients with BRAFi-
associated proliferative skin lesions and found all to be negative,
whereas 5/9 (56%) were positive for HPV of predominantly beta-
PV types (Falchook et al., 2016). A case report by the same
authors also failed to detect MCPyV in a normal skin of a
patient with BRAFi-cSCC (Falchook et al., 2013). Other HPyV
have not been analyzed in normal skin from BRAFi-exposed
individuals. These data provide a possible signal that HPyV6
and 7 are overrepresented in BRAFi-cSCC, with our findings
of 36 and 54% positivity, respectively. However, as normal skin
is frequently positive for MCPyV, our findings in BRAFi-cSCC
are less convincing. However, this interpretation is speculative
and needs to be confirmed in future studies that specifically
include matched normal skin samples from BRAFi-exposed
individuals.
To date, there have been no functional studies specifically
addressing the role of HPyVs in BRAFi-cSCC. The oncogenic
potential of MCPyV is well established in MCC (Church and
Nghiem, 2015; Paulson et al., 2017) and it is plausible that
the large and small T-antigen oncoproteins may be relevant
in BRAFi-cSCC. To date, none of the 12 other HPyVs have
been implicated in causing cancer (Church and Nghiem, 2015).
However, recent in vitro studies have indicated that MCPyV,
HPyV6, and TSPyV can all induce cellular MAPK pathways (Wu
et al., 2016, 2017a,b). It is therefore, plausible that such activity
may act synergistically with BRAFi-induced MAPK upregulation
and contribute to driving squamoproliferative lesions.
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Co-detection of HPV and HPyV
Human papillomavirus and HPyV were co-detected in the
majority of virus positive lesions, usually at low copy number.
There were no clear associations of specific types, although beta-
PVs and MCPyV were most commonly co-detected, as previously
reported (Falchook et al., 2013, 2016; Cohen et al., 2015). Our
interpretation of these data is limited by the fact we have only
examined normal skin for HPVs and not for HPyVs. However,
co-detection of these potentially oncogenic viruses in BRAFi-
cSCC remains an important observation. Although it is not
possible from these data to conclude whether one virus type
is biologically more relevant than another in either driving
the virus features seen histologically, the potential for their
interaction in playing an oncogenic role merits further functional
investigation. In particular, it is plausible that the ability of HPyV
to upregulate MAPK and the effects of MAPK upregulation on
HPV replication, infectivity and stability may act synergistically
in enhancing the oncogenic potential of both in contributing
to the pathogenesis of BRAFi-associated squamoproliferative
lesions.
Virus Status and Genetic Alterations
We have previously used SNP array analysis to show that UV-
associated well-differentiated cSCC have significantly different
patterns of chromosomal aberrations compared with moderately
and poorly differentiated cSCC (Purdie et al., 2009). Although
BRAFi-cSCCs are histologically similar to well- differentiated
sporadic cSCC, we have shown that they do not display the
characteristic gross chromosomal aberrations typically associated
with well-differentiated cSCC. This possibly reflects the shorter
time course and more prominent role for MAPK upregulation
induced by BRAFi, rather than through lifetime accumulated
UVR-induced DNA damage, as seen in sporadic UV-associated
cSCC (Lambert et al., 2014). Arguably, however, it also provides
circumstantial evidence for alternative etiological agents such as
oncogenic viruses.
At the individual gene level, as previously reported, we
found a significantly higher level of HRAS mutations in BRAFi-
cSCC compared with non-BRAFi-cSCC (South et al., 2014). In
the current study, we specifically sought a possible association
with virus status in HRAS mutated compared with HRAS wild
type lesions. This may provide insights into the mechanisms
underlying carcinogenesis in BRAFi-cSCC that are additional to
mutant HRAS-associated upregulation of the MAPK pathway
and, for example, related to viral oncogenes. However, no clear
correlation emerged between virus and HRAS status. We also
specifically looked for evidence of an inverse association between
the detection of virus and mutational burden in terms of the
numbers of mutated genes, as is seen in MCC (Harms et al., 2015;
Wong et al., 2015; Goh et al., 2016; Becker et al., 2017; Starrett
et al., 2017; Carter et al., 2018). Once again, no clear association
emerged, although this study may have been underpowered to
detect such an association.
CONCLUSION
Despite the suggestive clinical and histologic evidence, a
compelling experimental murine model and genetic evidence that
HRAS mutations are absent in a significant proportion of BRAFi-
induced squamoproliferative skin lesions, the contribution of
HPVs and HPyVs to the development of these lesions suggested
by results from previous studies remains inconclusive. The data
presented here provide further circumstantial evidence for a
possible role for HPV and HPyV. They also point to possible
synergistic interactions between these potentially oncogenic skin
viruses. Given the major increase predicted in adjuvant use of
these agents in the near future, further research into the role
of these and possibly other existing or novel members of the
human skin virome is justified and may provide insights into
the pathogenesis of other BRAF-induced skin disorders and
malignancies.
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